Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Repare Therapeutics Inc. - Common Shares (NQ:RPTX)

1.830 +0.060 (+3.39%)
Streaming Delayed Price Updated: 3:55 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Repare Therapeutics Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 Next >
Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Analyst Expectations for Repare Therapeutics's Future
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 9, 2023
 
Via Benzinga
Repare Therapeutics Releases Early Anticancer Activity From Its Monotherapy, Combination Trials
Repare Therapeutics Inc (NASDAQ: RPTX) reported initial proof of concept monotherapy data from its Phase 1 MYTHIC trial evaluating lunresertib (RP-6306) in molecularly selected  
Via Benzinga
Repare Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference
From Repare Therapeutics Inc.
Via Business Wire
Recap: Repare Therapeutics Q1 Earnings
 
Via Benzinga
Analyst Expectations for Repare Therapeutics's Future
 
Via Benzinga
Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights
From Repare Therapeutics Inc.
Via Business Wire
4 Analysts Have This to Say About Repare Therapeutics
 
Via Benzinga
Repare Therapeutics's Return On Capital Employed Insights
 
Via Benzinga
Repare Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors
From Repare Therapeutics Inc.
Via Business Wire
NASDAQ: RPTX Investor Alert: Investigation over Potential Wrongdoing at Repare Therapeutics Inc.
San Diego, CA -- (SBWIRE) -- 04/28/2023 -- Certain directors of Repare Therapeutics Inc. are under investigation over potential breaches of fiduciary duties. 
Via SBWire
Repare Therapeutics Presents Initial Clinical Data from the Phase 1/2 TRESR and ATTACC Trials Evaluating Camonsertib in Combination with Three PARP Inhibitors at the 2023 AACR Annual Meeting
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Announces Plenary Oral Presentation at the 2023 AACR Annual Meeting on Camonsertib and Additional Data Presentations on RP-6306
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Inc. (NASDAQ:RPTX) Investor Investigation over Possible Violations of Securities Laws
San Diego, CA -- (SBWIRE) -- 02/22/2023 -- An investigation shares over potential securities laws violations by Repare Therapeutics Inc. 
Via SBWire
Cathie Wood Has Been Building Stakes In Two Little-Known Stocks
Cathie Wood – the billionaire investor who recently called her flagship fund “the new Nasdaq” has been loading up on shares of the following two small-cap stocks in recent days. 
Via Talk Markets
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Repare Therapeutics Inc. (RPTX) Investigation
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
 
Via Benzinga
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Receives $1.5 Million (¥200 million) Payment from Ono Pharmaceuticals
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans
From Repare Therapeutics Inc.
Via Business Wire
Credit Suisse, Autodesk And Other Big Losers From Wednesday
U.S. stocks closed higher on Wednesday, with the Nasdaq Composite gaining more than 100 points. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
Quest Diagnostics To Plunge 16%? Here Are 5 Other Price Target Changes For Thursday
 
Via Benzinga
Repare Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
From Repare Therapeutics Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.